Drs Greten and El-Khoueiry discuss the emergence of checkpoint inhibition therapy in the treatment of advanced HCC.
This activity is intended for oncologists, gastroenterologists, surgeons, and nurses.
The goal of this activity is to review the latest data on the efficacy and safety of immune checkpoint inhibitors in the management of patients with advanced hepatocellular carcinoma (HCC).
Approximate Time to Complete: 30 minutes
Credit Available: Mar. 09, 2018 - Mar. 09, 2019
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Increase knowledge regarding the role of immune checkpoint inhibitors in the management of advanced HCC
- Increase knowledge regarding identification of immune-related adverse events in patients with HCC who receive a checkpoint inhibitor